Science Daily·3 min read·medium
Oral GLP-1 drugs may quiet the brain’s food craving circuit
✦AI Summary
Researchers have identified a new neural pathway in the brain that oral GLP-1 medications target to reduce hedonic eating. This discovery suggests these drugs could potentially treat reward-based conditions like substance use disorder in addition to obesity.
Popular weight-loss and diabetes medications such as semaglutide and Ozempic belong to a broader group known as GLP-1 drugs. A study funded by the National Institutes of Health (NIH) has now identified a previously unrecognized way that some newer oral drugs in this class may affect the brain.
sciencehealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in